DES market share decline prompts Boston update
This article was originally published in Clinica
Executive Summary
Boston Scientific lowered its sales guidance for 2005 at an analyst meeting during the EuroPCR (Paris Course on Revascularisation) conference in Paris this week, indicating that its worldwide market share in drug-eluting stents will probably not be 58-59% as previously expected. Sales of its Taxus DES are now likely to be $2.6-2.8bn for the year, representing a market share of 52-55%. The company said group sales would probably increase by 13-17% to $6.4-6.6bn. Prior predictions were in the range of $6.4-6.7bn.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.